Fairvalue-Calculator Fairvalue-Calculator

Fresenius Medical Care AG (FMS) Fair Value & Analysis

Healthcare · US · Market cap $12.7B

Price$23.85
Fair Value$45.58
Upside+91.1%
Quality95/100
Evidence: High Range $27.83 – $56.98

Analysis

Fresenius Medical Care AG (FMS) currently trades at $23.85, while our model-based Fair Value estimate is $45.58 — implying the stock looks roughly 91.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for wate…

Open the full interactive analysis →

Similar stocks

HCA Healthcare, Inc (H1CA34) -74% Fresenius SE (FSNUY) -27% 5225 (5225) -64% IHHHF (IHHHF) -57% Tenet Healthcare Corporation (THC) +70% Rede D'Or São Luiz S.A (RDOR3) +42%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.